GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (STU:1K0) » Definitions » Total Equity

IGM Biosciences (STU:1K0) Total Equity : €148.35 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences Total Equity?

IGM Biosciences's total equity for the quarter that ended in Mar. 2024 was €148.35 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

IGM Biosciences Total Equity Historical Data

The historical data trend for IGM Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences Total Equity Chart

IGM Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial 216.21 313.85 216.74 271.18 186.37

IGM Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 223.63 238.69 237.87 186.37 148.35

IGM Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

IGM Biosciences's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=388.268-201.902
=186.37

IGM Biosciences's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=346.041-197.689
=148.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGM Biosciences Total Equity Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IGM Biosciences (STU:1K0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (STU:1K0) » Definitions » Total Equity
Comparable Companies
OVID VNDA DRTS YMAB XERS NRIX CMPX CELC AVIR ACIU OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IGMS:USA
Address
325 East Middlefield Road, Mountain View, CA, USA, 94043
Website
https://www.igmbio.com
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

IGM Biosciences (STU:1K0) Headlines

No Headlines